EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC

David Planchard, Pasi A Jänne, Ying Cheng, James C-H Yang, Noriko Yanagitani, Sang-We Kim, Shunichi Sugawara, Yan Yu, Yun Fan, Sarayut L Geater, Konstantin Laktionov, Chee K Lee und 10 weitere

New England Journal of Medicine · 23.11.2023 · 389 (21) · 1935-1948

DOI: 10.1056/nejmoa2306434 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 23.11.2023. Verfasst von David Planchard und 21 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medical Oncology, Institut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Villejuif, and the Fa…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 782-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsAntineoplastic AgentsHumansAniline CompoundsAntineoplastic Combined Chemotherapy ProtocolsErbB ReceptorsMutationPemetrexedAcrylamidesIndolesPyrimidines

Substanzen

Aniline CompoundsErbB ReceptorsPemetrexedProtein Kinase InhibitorsAntineoplastic AgentsEGFR protein, humanosimertinibAcrylamidesIndolesPyrimidines

Autor:innen und Institutionen

  • From the Department of Medical Oncology, Institut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Villejuif, and the Faculty of Medicine, Paris-Saclay University, Paris - both in France (D.…

ORCID-Profile: Jonathan Goldman

Förderung

  • AstraZeneca

Zitieren

APA

Planchard, D., Jänne, P. A., Cheng, Y., Yang, J. C., Yanagitani, N., Kim, S. W., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., Laktionov, K., Lee, C. K., Valdiviezo, N., Ahmed, S., Maurel, J. M., Andrasina, I., Goldman, J., Ghiorghiu, D., Rukazenkov, Y., …, & FLAURA2 Investigators (2023). Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC. New England Journal of Medicine, 389(21), 1935-1948. https://doi.org/10.1056/nejmoa2306434

Vancouver

Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, et al. Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC. New England Journal of Medicine. 2023;389(21):1935-1948. doi:10.1056/nejmoa2306434

BibTeX
@article{Planchard2023,
  author = {Planchard, David and Jänne, Pasi A and Cheng, Ying and Yang, James C-H and Yanagitani, Noriko and Kim, Sang-We and Sugawara, Shunichi and Yu, Yan and Fan, Yun and Geater, Sarayut L and Laktionov, Konstantin and Lee, Chee K and Valdiviezo, Natalia and Ahmed, Samreen and Maurel, Jean-Marc and Andrasina, Igor and Goldman, Jonathan and Ghiorghiu, Dana and Rukazenkov, Yuri and Todd, Alex and Kobayashi, Kunihiko and FLAURA2 Investigators, FLAURA2 Investigators},
  title = {Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {21},
  pages = {1935--1948},
  doi = {10.1056/nejmoa2306434}
}
Kostenlos starten →